Effects of chronic treatment with 1-sulpiride and haloperidol on central dopamine turnover evaluated in dopamine cell body and nerve terminal-rich areas. 1980

L F Agnati, and K Andersson, and K Fuxe, and F Benfenati, and P Cortelli, and R D'Alessandro, and S O Ogren

Catecholamine levels and turnover have been analyzed in DA cell body and in terminal-rich areas of the midbrain, diencephalon, and forebrain 48 hr following a 2-week treatment with l-sulpiride and haloperidol. At this time interval behavioral supersensitivity to DA agonists has been demonstrated. No changes in DA turnover are found in the DA cell body groups A9 and A10 or in various DA terminals of forebrain, with a possible exception for the diffuse type of DA terminals in the tuberculum olfactorium where a reduction of DA turnover rate is observed. In the median eminence of the l-sulpiride-treated group, however, DA turnover increases are observed. It is suggested that the lack of amine turnover changes in most of the DA terminal systems of the brain is related to the development of DA receptor supersensitivity in both striatal and limbic areas, balancing the DA receptor blocking activity of the neuroleptic drugs still present in the tissue of the brain.

UI MeSH Term Description Entries
D008297 Male Males
D009411 Nerve Endings Branch-like terminations of NERVE FIBERS, sensory or motor NEURONS. Endings of sensory neurons are the beginnings of afferent pathway to the CENTRAL NERVOUS SYSTEM. Endings of motor neurons are the terminals of axons at the muscle cells. Nerve endings which release neurotransmitters are called PRESYNAPTIC TERMINALS. Ending, Nerve,Endings, Nerve,Nerve Ending
D009714 Nucleus Accumbens Collection of pleomorphic cells in the caudal part of the anterior horn of the LATERAL VENTRICLE, in the region of the OLFACTORY TUBERCLE, lying between the head of the CAUDATE NUCLEUS and the ANTERIOR PERFORATED SUBSTANCE. It is part of the so-called VENTRAL STRIATUM, a composite structure considered part of the BASAL GANGLIA. Accumbens Nucleus,Nucleus Accumbens Septi,Accumbens Septi, Nucleus,Accumbens Septus, Nucleus,Accumbens, Nucleus,Nucleus Accumbens Septus,Nucleus, Accumbens,Septi, Nucleus Accumbens,Septus, Nucleus Accumbens
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D002395 Catecholamines A general class of ortho-dihydroxyphenylalkylamines derived from TYROSINE. Catecholamine,Sympathin,Sympathins
D002421 Caudate Nucleus Elongated gray mass of the neostriatum located adjacent to the lateral ventricle of the brain. Caudatus,Nucleus Caudatus,Caudatus, Nucleus,Nucleus, Caudate
D004298 Dopamine One of the catecholamine NEUROTRANSMITTERS in the brain. It is derived from TYROSINE and is the precursor to NOREPINEPHRINE and EPINEPHRINE. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (RECEPTORS, DOPAMINE) mediate its action. Hydroxytyramine,3,4-Dihydroxyphenethylamine,4-(2-Aminoethyl)-1,2-benzenediol,Dopamine Hydrochloride,Intropin,3,4 Dihydroxyphenethylamine,Hydrochloride, Dopamine
D006220 Haloperidol A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279) Haldol
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013469 Sulpiride A dopamine D2-receptor antagonist. It has been used therapeutically as an antidepressant, antipsychotic, and as a digestive aid. (From Merck Index, 11th ed) Aiglonyl,Arminol,Deponerton,Desisulpid,Digton,Dogmatil,Dolmatil,Eglonyl,Ekilid,Guastil,Lebopride,Meresa,Pontiride,Psicocen,Sulp,Sulperide,Sulpitil,Sulpivert,Sulpor,Synédil,Tepavil,Vertigo-Meresa,neogama,vertigo-neogama,Vertigo Meresa,vertigo neogama

Related Publications

L F Agnati, and K Andersson, and K Fuxe, and F Benfenati, and P Cortelli, and R D'Alessandro, and S O Ogren
January 1988, Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica,
L F Agnati, and K Andersson, and K Fuxe, and F Benfenati, and P Cortelli, and R D'Alessandro, and S O Ogren
May 1989, Neurochemical research,
L F Agnati, and K Andersson, and K Fuxe, and F Benfenati, and P Cortelli, and R D'Alessandro, and S O Ogren
June 1976, Neuroscience letters,
L F Agnati, and K Andersson, and K Fuxe, and F Benfenati, and P Cortelli, and R D'Alessandro, and S O Ogren
January 1982, Brain research,
L F Agnati, and K Andersson, and K Fuxe, and F Benfenati, and P Cortelli, and R D'Alessandro, and S O Ogren
August 1981, Bollettino della Societa italiana di biologia sperimentale,
L F Agnati, and K Andersson, and K Fuxe, and F Benfenati, and P Cortelli, and R D'Alessandro, and S O Ogren
May 1981, Experientia,
L F Agnati, and K Andersson, and K Fuxe, and F Benfenati, and P Cortelli, and R D'Alessandro, and S O Ogren
October 1981, Journal of neurochemistry,
L F Agnati, and K Andersson, and K Fuxe, and F Benfenati, and P Cortelli, and R D'Alessandro, and S O Ogren
June 1983, Life sciences,
L F Agnati, and K Andersson, and K Fuxe, and F Benfenati, and P Cortelli, and R D'Alessandro, and S O Ogren
January 1995, Neurochemical research,
L F Agnati, and K Andersson, and K Fuxe, and F Benfenati, and P Cortelli, and R D'Alessandro, and S O Ogren
October 1986, European journal of pharmacology,
Copied contents to your clipboard!